This new international conference will offer a forum for an update on recent developments and future challenges relating to ‘Biomarkers of Vaccine/Adjuvant Potency and Safety’. The…
Researchers have announced that the rVSV-ZEBOV vaccine has shown 100 % effectiveness in a Phase III large-scale trial of over 7000 people in Guinea. These results suggest that the…
With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-the-art technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine…
The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) – financed under the EU 7th Framework Programme (FP7) – launched a strategy setting…
The Science and Technology Options Assessment (STOA) of the European Parliament, organizes an event “Working Breakfast on Vaccine Research and Development in Europe”. This is…
The efficacy and effectiveness of rVSV-vectored vaccine in preventing Ebola virus disease was demostrated in a Guinea ring vaccination, open-label, cluster-randomised trail. The resultsadd weight…
Professor Claire-Anne Siegrist from the University of Geneva in Switzerland, the principal investigator of the Geneva clinical trial, and Donata Medaglini the coordinator of the VSV-EBOVAC project,…
Scientists are invited to submit original articles by following this link
The VSV-EBOVAC Consortium has collaborated in the study “A dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and…
The article “Immunomonitoring of human responses to the rVSV-ZEBOV Ebola Vaccine” was published in Current Opinion in Virology journal with the acknowledgment of the VSV-EBOVAC…